Lycopene synergistically enhances quinacrine action to inhibit Wnt-TCF signaling in breast cancer cells through APC

Carcinogenesis

Volumn 34, Issue 2, 2013, Pages 277-286

  Preet, Ranjan ^a   Mohapatra, Purusottam ^a   Das, Dipon ^a   Satapathy, Shakti R ^a   Choudhuri, Tathagata ^b   Wyatt, Michael D ^c   Kundu, Chanakya N ^a  

^a KIIT UNIVERSITY   (India)

^b Department of Infection Biology   (India)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; AXIN; BETA CATENIN; CYCLIN D1; DNA TOPOISOMERASE; ETOPOSIDE; GLYCOGEN SYNTHASE KINASE 3BETA; LYCOPENE; MEPACRINE; T CELL FACTOR PROTEIN; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CONTROLLED STUDY; DNA DAMAGE; DRUG ACTIVITY; DRUG POTENTIATION; GENE SILENCING; HUMAN; HUMAN CELL; LC 50; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; WNT SIGNALING PATHWAY;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; BREAST NEOPLASMS; CAROTENOIDS; CELL CYCLE; CELL PROLIFERATION; COMET ASSAY; CYCLIN D1; DRUG SYNERGISM; ETOPOSIDE; FEMALE; FLOW CYTOMETRY; GLYCOGEN SYNTHASE KINASE 3; HUMANS; PROMOTER REGIONS, GENETIC; QUINACRINE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; T CELL TRANSCRIPTION FACTOR 1; TCF TRANSCRIPTION FACTORS; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; WNT PROTEINS;

EID: 84873534116     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs351     Document Type: Article

References (53)

1. Clevers,H. (2006) Wnt/beta-catenin signaling in development and disease. Cell, 127, 469-480.
2. Giles,R.H. et al. (2003) Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta, 1653, 1-24.
3. Khalil,S. et al. (2012) Activation status of Wnt/ß-catenin signaling in normal and neoplastic breast tissues: relationship to HER2/neu expression in human and mouse. PLoS ONE, 7, e33421.
4. Liu,C. et al. (1999) beta-Trcp couples beta-catenin phosphorylation-degradation and regulates Xenopus axis formation. Proc. Natl. Acad. Sci. U.S.A., 96, 6273-6278.
5. Liu,C. et al. (2002) Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell, 108, 837-847.
6. Zeng,X. et al. (2005) A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature, 438, 873-877.
7. Zeng,X. et al. (2008) Initiation of Wnt signaling: control of Wnt coreceptor Lrp6phosphorylation/activation via frizzled, dishevelled and axin functions. Development, 135, 367-375.
8. Jaiswal,A.S. et al. (2006) Mechanism of adenomatous polyposis coli (APC)-mediated blockage of long-patch base excision repair. Biochemistry, 45, 15903-15914.
9. Willert,K. et al. (2006) Wnt signaling: is the party in the nucleus? Genes Dev., 20, 1394-1404.
10. Kinzler,K.W. et al. (1996) Lessons from hereditary colorectal cancer. Cell, 87, 159-170.
11. Yang,J. et al. (2006) Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells. J. Biol. Chem., 281, 17751-17757.
12. Huang,S.M. et al. (2009) Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature, 461, 614-620.
13. Chen,B. et al. (2009) Small molecule-mediated disruption of Wntdependent signaling in tissue regeneration and cancer. Nat. Chem. Biol., 5, 100-107.
14. Liu,C. et al. (2010) Destruction of a destructor: a new avenue for cancer therapeutics targeting the Wnt pathway. J. Mol. Cell Biol., 2, 70-73.
15. Barker,N. et al. (2006) Mining the Wnt pathway for cancer therapeutics. Nat. Rev. Drug Discov., 5, 997-1014.
16. Takahashi-Yanaga,F. et al. (2010) Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin. Cancer Res., 16, 3153-3162.
17. Chen,Z. et al. (2009) 2,4-Diamino-quinazolines as inhibitors of betacatenin/ Tcf-4 pathway: potential treatment for colorectal cancer. Bioorg. Med. Chem. Lett., 19, 4980-4983.
18. Lepourcelet,M. et al. (2004) Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell, 5, 91-102.
19. Ryu,M.J. et al. (2008) Natural derivatives of curcumin attenuate the Wnt/ beta-catenin pathway through down-regulation of the transcriptional coactivator p300. Biochem. Biophys. Res. Commun., 377, 1304-1308.
20. Su,L.K. et al. (1993) Association of the APC tumor suppressor protein with catenins. Science, 262, 1734-1737.
21. Roccaro,A.M. et al. (2008) Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia. Clin. Cancer Res., 14, 1849-1858.
22. Gurova,K.V. et al. (2005) Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc. Natl. Acad. Sci. U.S.A., 102, 17448-17453.
23. Preet,R. et al. (2012) Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity. Int. J. Cancer, 130, 1660-1670.
24. Guo,C. et al. (2009) 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways. Oncogene, 28, 1151-1161.
25. Ehsanian,R. et al. (2011) Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers. Cell Commun. Signal, 15, 9-13.
26. Demeunynck,M. et al. (2001) Interest of acridine derivatives in the anticancer chemotherapy. Curr. Pharm. Des., 7, 1703-1724.
27. Woynarowski,J.M. et al. (1984) DNA damage in HeLa s3 cells by an antitumor drug Ledakrin and other antitumor 1-nitro-9-aminoacridines. Chem. Biol. Interact., 49, 311-328.
28. Gurova,K. (2009) New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents. Future Oncol., 5, 1685-1704.
29. Narayan,S. et al. (2005) Tumor suppressor APC blocks DNA polymerase beta-dependent strand displacement synthesis during long patch but not short patch base excision repair and increases sensitivity to methylmethane sulfonate. J. Biol. Chem., 280, 6942-6949.
30. Kundu,C.N. et al. (2007) Cigarette smoke condensate-induced level of adenomatous polyposis coli blocks long-patch base excision repair in breast epithelial cells. Oncogene, 26, 1428-1438.
31. Huang,L. et al. (2007) Functional interaction of DNA topoisomerase IIalpha with the beta-catenin and T-cell factor-4 complex. Gastroenterology, 133, 1569-1578.
32. Teodoro,A.J. et al. (2012) Effect of lycopene on cell viability and cell cycle progression in human cancer cell lines. Cancer Cell Int., 12, 36.
33. Sarkar Fazlul,H. et al. (2010) The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer. Cancer Metastasis Rev., 29, 383-394.
34. Limpens,J. et al. (2004) Re: Prostate carcinogenesis in N-methyl-Nnitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J. Natl. Cancer Inst., 96, 554; author reply 554- 554; author reply 555.
35. Kucuk,O. et al. (2001) Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol. Biomarkers Prev., 10, 861-868.
36. Kucuk,O. et al. (2002) Effects of lycopene supplementation in patients with localized prostate cancer. Exp. Biol. Med. (Maywood), 227, 881-885.
37. Wertz,K. (2009) Lycopene effects contributing to prostate health. Nutr. Cancer, 61, 775-783.
38. Uppala,P.T. et al. (2012) Selective inhibition of cell proliferation by lycopene in MCF-7 breast cancer cells in vitro: a proteomic analysis. Phytother. Res., doi: 10.1002/ptr.4764 [Epub ahead of print].
39. Mohapatra,P. et al. (2011) 5-fluorouracil increases the chemopreventive potentials of resveratrol through DNA damage and MAPK signaling pathway in human colorectal cancer cells. Oncol. Res., 19, 311-321.
40. Sun,L. et al. (2012) Role of TRPM2 in H(2)O(2)-induced cell apoptosis in endothelial cells. PLoS One, 7(8):e43186. doi: 10.1371.
41. Kuo,C.C. et al. (2011) Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors. Free Radic. Biol. Med., 51, 2195-2209.
42. Aggarwal,B.B. et al. (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol., 71, 1397-1421.
43. Abu-Remaileh,M. et al. (2010) Oct-3/4 regulates stem cell identity and cell fate decisions by modulating Wnt/β-catenin signalling. EMBO J., 29, 3236-3248.
44. Gerard,B. et al. (2011) Rad6B acts downstream of Wnt signaling to stabilize β-catenin: implications for a novel Wnt/β-catenin target. J. Mol. Signal., 6, 6.
45. Rubinfeld,B. et al. (1997) Loss of beta-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene. Cancer Res., 57, 4624-4630.
46. Munemitsu,S. et al. (1995) Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc. Natl. Acad. Sci. U.S.A., 92, 3046-3050.
47. Rubinfeld,B. et al. (1993) Association of the APC gene product with betacatenin. Science, 262, 1731-1734.
48. Su,Y. et al. (2007) Expression profiling of rat mammary epithelial cells reveals candidate signaling pathways in dietary protection from mammary tumors. Physiol. Genomics, 30, 8-16.
49. Eklof,S.K. et al. (2001) Molecular mechanisms of betacatenin recognition by adenomatous polyposis coli revealed by the structure of an APC-betacatenin complex. EMBO J., 20, 6203-6212.
50. Hamada,F. et al. (2004) The APC tumor suppressor binds to C-terminal binding protein to divert nuclear beta-catenin from TCF. Dev. Cell, 7, 677-685.
51. Sierra,J. et al. (2006) The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes. Genes Dev., 20, 586-600.
52. Schneikert,J. et al. (2011) APC mutations in colorectal tumours from FAP patients are selected for CtBP-mediated oligomerization of truncated APC. Hum. Mol. Genet., 20, 3554-3564.
53. Wang,Y. et al. (2008) Interaction between tumor suppressor adenomatous polyposis coli and topoisomerase IIalpha: implication for the G2/M transition. Mol. Biol. Cell, 19, 4076-4085.